News
阿斯利康公佈第三季度業績，總收入同比增長 12% 至 151.91 億美元，核心每股盈利為 2.38 美元，高於市場預期的 2.27 美元，受惠於重磅癌症及糖尿病藥物銷售理想。首九個月收入同比增長 10% 至 432.36 億美元，核心每股盈利為 7.04 美元。公司重申全年收入將實現高單位數增長，以及核心每股盈利低雙位數增長，與市場預期基本一致。公司計劃宣佈 2025 年全年股息為每股 3.2 美元，而去年為 3.1 美元。
Source: 長灣資訊 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments